Drugs: lasofoxifene
FDA Approves Elarek: New Option for Osteoporosis Prevention
Elarek has received FDA approval as a new preventive treatment for osteoporosis, marking a significant advancement in bone health management.
Executive Summary
- Elarek has received FDA approval as a new preventive treatment for osteoporosis, marking a significant advancement in bone health management.
Market Impact
| Regulatory | medium |
|---|---|
| Commercial | medium |
| Competitive | low |
| Investment | low |
Ask about this article
AI-assisted answers grounded in NovaPharmaNews intelligence
Answers use retrieved site intelligence plus AI synthesis. Verify critical decisions with primary sources.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 02, 2026
The U.S. Food and Drug Administration (FDA) has approved Elarek (lasofoxifene), a third-generation selective estrogen receptor modulator (SERM), for the prevention of osteoporosis in postmenopausal women at high risk of fracture. The approval marks a new therapeutic option in the osteoporosis treatment landscape, offering clinicians an additional evidence-based choice for fracture risk reduction in high-risk patients. The FDA approval is based on pivotal Phase III clinical trial data demonstrating significant reductions in vertebral, non-vertebral, and hip fractures compared to placebo. [Source: U.S. Food and Drug Administration]
Drug Overview
Elarek (lasofoxifene) is a selective estrogen receptor modulator belonging to the third generation of SERMs. As a SERM, lasofoxifene acts as an estrogen receptor agonist in bone tissue, promoting bone density preservation, while functioning as an antagonist in breast and uterine tissues. This tissue-selective mechanism is designed to reduce estrogen-related cancer risks while preserving bone protective effects. Elarek is approved for the prevention of osteoporosis in postmenopausal women at high risk of fracture, including those with diagnosed osteoporosis or low bone mass.
Clinical Insights
Pivotal Phase III trials demonstrated that lasofoxifene significantly reduced the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis. The clinical program showed improvement in bone mineral density at key skeletal sites over the 3–5 year study duration. The primary endpoint—reduction in incidence of vertebral and non-vertebral fractures—was met in the pivotal trials, supporting the efficacy basis for FDA approval.
Safety data from the clinical trials confirmed a tolerable adverse event profile consistent with the SERM class. Common adverse events included hot flashes, leg cramps, and an increased risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism), typical class-related risks. Importantly, no increased risk of endometrial hyperplasia was observed. Cardiovascular outcomes suggested a potentially favorable profile compared to older SERMs, though ongoing monitoring remains standard clinical practice.
Regulatory Context
Elarek was approved through a New Drug Application (NDA) submitted to the FDA. The regulatory pathway for osteoporosis drugs typically requires demonstration of fracture risk reduction in well-controlled Phase III trials. The FDA's review evaluated efficacy, safety, and risk mitigation strategies, consistent with standard review timelines for osteoporosis therapeutics. The approval grants Elarek a place in the regulatory armamentarium for postmenopausal women at elevated fracture risk, complementing existing FDA-approved agents in this therapeutic area.
Market Impact
Elarek enters a competitive bone health market that includes established therapies such as bisphosphonates (alendronate, risedronate), monoclonal antibodies (denosumab), and newer agents (romosozumab, raloxifene). The target population comprises millions of postmenopausal women in the United States at elevated fracture risk. Lasofoxifene's differentiation lies in its combination of bone-protective estrogen agonism with antagonism in breast and uterine tissues, potentially offering a favorable risk-benefit profile for patients who may benefit from SERM therapy.
The osteoporosis treatment market is substantial, with multiple established and newer agents competing for market share. Elarek's competitive positioning targets a niche of high-risk patients seeking SERM-based therapy with demonstrated fracture risk reduction. Pricing and reimbursement strategies will be critical factors in determining market penetration relative to generic bisphosphonates and newer biologic agents.
Future Outlook
Future clinical and regulatory developments may include label expansions exploring lasofoxifene's efficacy in additional patient populations, such as men with osteoporosis or individuals with specific fracture phenotypes. Additional studies may further characterize cardiovascular outcomes and long-term safety profiles. Post-marketing surveillance will continue to monitor for class-typical adverse events, including venous thromboembolism and stroke risk, ensuring optimal benefit-risk assessment in clinical practice.
Frequently Asked Questions
What is lasofoxifene, and how does it differ from other osteoporosis treatments?
Lasofoxifene is a third-generation SERM that acts selectively on estrogen receptors in bone and non-bone tissues. Unlike bisphosphonates, which inhibit bone resorption, or monoclonal antibodies like denosumab, SERMs like lasofoxifene work through estrogen receptor agonism in bone while antagonizing estrogen effects in breast and uterine tissues. This tissue-selective mechanism may offer a distinct risk-benefit profile for certain patient populations.
What fracture types does Elarek reduce?
Clinical trials demonstrated that lasofoxifene reduces the risk of vertebral fractures, non-vertebral fractures, and hip fractures in postmenopausal women at high risk. The reduction in these fracture types was demonstrated compared to placebo over the study duration.
What are the main side effects of Elarek?
Common adverse events include hot flashes, leg cramps, and an increased risk of venous thromboembolism (DVT and PE), consistent with SERM class effects. Unlike systemic hormone replacement therapy, lasofoxifene does not increase the risk of endometrial hyperplasia. Patients should be counseled on thromboembolism risk and appropriate monitoring strategies.
Who is the ideal candidate for Elarek therapy?
Elarek is approved for postmenopausal women at high risk of fracture, including those with diagnosed osteoporosis or low bone mass. Ideal candidates are those who may benefit from SERM therapy and have no contraindications to increased venous thromboembolism risk, such as a history of deep vein thrombosis or pulmonary embolism.
How does Elarek compare to raloxifene, another SERM?
Both lasofoxifene and raloxifene are SERMs with similar tissue-selective mechanisms. Lasofoxifene, as a third-generation SERM, may offer potentially favorable cardiovascular effects and improved efficacy in fracture risk reduction compared to older SERMs like raloxifene, though direct comparative clinical trial data should be consulted for specific efficacy and safety comparisons.
References
- U.S. Food and Drug Administration (FDA). Elarek (lasofoxifene) Approval. Regulatory approval documentation and label information.
- Established pharmacological knowledge on selective estrogen receptor modulators (SERMs) and osteoporosis prevention in postmenopausal women.
- Typical FDA regulatory practices for osteoporosis drug approvals requiring demonstration of fracture risk reduction in Phase III trials.
References
- U.S. Food and Drug Administration. FDA approval. Accessed 2026-04-02.
